Abstract

Obstructive lung diseases, such as chronic obstructive pulmonary disease, asthma, or non-cystic fibrosis bronchiectasis, share some major pathophysiological features: small airway involvement, dysregulation of adaptive and innate pulmonary immune homeostasis, mucus hyperproduction, and/or hyperconcentration. Mucus regulation is particularly valuable from a therapeutic perspective given it contributes to airflow obstruction, symptom intensity, disease severity, and to some extent, disease prognosis in these diseases. It is therefore crucial to understand the mucus constitution of our patients, its behavior in a stable state and during exacerbation, and its regulatory mechanisms. These are all elements representing potential therapeutic targets, especially in the era of biologics. Here, we first briefly discuss the composition and characteristics of sputum. We focus on mucus and mucins, and then elaborate on the different sample collection procedures and how their quality is ensured. We then give an overview of the different direct analytical techniques available in both clinical routine and more experimental settings, giving their advantages and limitations. We also report on indirect mucus assessment procedures (questionnaires, high-resolution computed tomography scanning of the chest, lung function tests). Finally, we consider ways of integrating these techniques with current and future therapeutic options. Cystic fibrosis will not be discussed given its monogenic nature.

Highlights

  • No increases in mucin gene expression have been found [51], suggesting that mucus is in a dehydrated state triggered potentially by local hypoxic inhibitions of cystic fibrosis transmembrane conductance regulator (CFTR) activity [52], or by fluid absorption enhanced by human neutrophil elastase (HNE) activity [53]

  • Mucus dysregulation could be considered as the be-all and end-all of certain obstructive lung diseases, such as asthma, Chronic obstructive pulmonary disease (COPD), or non-CF bronchiectasis

  • Despite the wide range of available methods for assessing mucus production and secretion, as well as the biophysical and biochemical properties of mucus, daily clinical practice has relied for years on clinical evaluation, chest high-resolution computed tomography (HRCT), cytology, and microbiology

Read more

Summary

Simoes and Esther Barreiro

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations

Role and Components
Regulation of Airway
Mucus and Mucins in Muco-Obstructive Lung Diseases
Chronic Obstructive Pulmonary Disease
Asthma
Non-Cystic Fibrosis Bronchiectasis
Flexible Bronchoscopy
Sputum
Direct Assessment of Human Airway Mucus and Mucins
Macroscopic Studies of Sputum
Limitations
Cytology be used in vivo with sample
Cytology
Microbiology
Histological Staining and Immunostaining
Molecular Assays
Semi-Quantitative and Quantitative Assessments of Mucin Proteins
Biophysical Properties and Rheology of Human Mucus
Ex Vivo Models
Respiratory Symptoms
Imaging
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call